The WSJ report that generic-drug giant Teva Pharmaceutical Industries Ltd. has agreed to acquire biopharmaceutical company CoGenesys Inc. for $400 million in cash.
The deal, which is expected to close by the end of June, is likely to stoke the debate about the role generic-drug makers should play in the emerging market for biological therapies.
No comments:
Post a Comment